Brought to you by 
Schwarz licenses Ranbaxy's BPH compound
26 Jul 2002
Executive Summary
Schwarz Pharma licensed exclusive US, Japanese, and European development and marketing rights to Ranbaxy Laboratories' RBx-2258 drug candidate for benign prostatic hyperplasia. The compound is in Phase I for the licensed territories, and in Phase II in India, where Ranbaxy retains rights.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schwarz licenses Ranbaxy's BPH compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice